Article Information
History
- November 12, 2018.
Article Versions
- Version 1 (June 18, 2018 - 11:52).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Slavka Baronikova1,
- Jim Purvis2,
- Eric Southam2,
- Julie Beeso2,
- Christopher C Winchester2 and
- Antonia Panayi1
- 1Shire International GmbH, Global Medical Affairs, Medical Shared Services, Zug, Switzerland
- 2Oxford PharmaGenesis, Oxford OX13 5QJ, UK
- Correspondence to: S Baronikova
, Shire International GmbH, Global Medical Affairs, Medical Shared Services, Zug, Switzerland; sbaronikova-c{at}shire.com (Tel: +32 2 7110298)
Posted November 12, 2018.
Commitments by the Biopharmaceutical Industry to Clinical Trial Transparency: The Evolving Environment
